Blood Brain Barrier Technologies Market Outlook to 2028 & 2033
December 13, 2024 09:11 ET
|
Research and Markets
Dublin, Dec. 13, 2024 (GLOBE NEWSWIRE) -- The "Blood Brain Barrier Technologies Market 2024" report has been added to ResearchAndMarkets.com's offering.The blood brain barrier technologies market...
EpimAb Biotherapeutics Announces Oral Presentation for EMB-06 (CND106) First-in-human (FIH) Phase I Study in Multiple Myeloma at the American Society of Hematology (ASH) 2024 Annual Meeting
December 05, 2024 20:00 ET
|
Shanghai EpimAb Biotherapeutics Co., Ltd.
SHANGHAI, Dec. 06, 2024 (GLOBE NEWSWIRE) -- EpimAb Biotherapeutics, a global clinical stage biotechnology company specializing in the development of bispecific antibodies, is pleased to announce the...
Complement Inhibitor Therapeutics Pipeline Developments Research Report 2024
December 05, 2024 10:36 ET
|
Research and Markets
Dublin, Dec. 05, 2024 (GLOBE NEWSWIRE) -- The "Complement Inhibitors - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering. The latest comprehensive analysis of the...
Folate Receptor alpha (FRa) Targeted Therapy Pipeline Review 2024: Drug Code/INN, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage
October 24, 2024 10:12 ET
|
Research and Markets
Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Folate Receptor alpha (FRa) Targeted Therapy Pipeline Review" report has been added to ResearchAndMarkets.com's offering. This product provides...
PSMA Targeted Therapy Pipeline Review 2024: Drug Code/INN, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage
October 24, 2024 10:01 ET
|
Research and Markets
Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "PSMA - Targeted Therapy Pipeline Review" report has been added to ResearchAndMarkets.com's offering. This product provides basic information on...
Bispecific Antibody Drug Conjugates Market Opportunity Outlook 2024-2029: China Leads Over 35 Candidates, Key Companies Pioneering BsADC are Amgen, Innovent Biologics, AstraZeneca
October 14, 2024 05:52 ET
|
Research and Markets
Dublin, Oct. 14, 2024 (GLOBE NEWSWIRE) -- The "Global Bispecific Antibody Drug Conjugates Clinical Trials, Regulatory Approvals & Future Market Opportunity Outlook 2029" report has been added to...
EpimAb Biotherapeutics Announces Upcoming Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 10, 2024 21:00 ET
|
Shanghai EpimAb Biotherapeutics Co., Ltd.
SHANGHAI, Oct. 11, 2024 (GLOBE NEWSWIRE) -- EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies and T-cell engagers, is pleased to...
EpimAb Biotherapeutics and Vignette Bio Announce Strategic Collaboration to Develop EMB-06, a BCMA×CD3 Bispecific Antibody
September 03, 2024 21:00 ET
|
Shanghai EpimAb Biotherapeutics Co., Ltd.
SHANGHAI and SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- EpimAb Biotherapeutics, Inc. (“EpimAb” or “EpimAb Biotherapeutics”) a clinical stage biopharmaceutical company specializing in the...
Global Biologics Contract Development and Manufacturing Organizations Market Report 2024-2029: End-to-end mRNA Services & Expanding Drug Capabilities to Support Anti-obesity Drugs Fuels Opportunities
July 31, 2024 09:41 ET
|
Research and Markets
Dublin, July 31, 2024 (GLOBE NEWSWIRE) -- The "Growth Opportunities in Biologics Contract Development and Manufacturing Organizations, 2024-2029" report has been added to ResearchAndMarkets.com's...
Vulvar Cancer Pipeline Insight 2024, with Key Focus on TAK-242, Vudalimab, PEN-866, Artesunate, IRX-2, ISA101, VicOryx, PRV111, PRGN-2009, ABI-2280 and CUE-101
April 16, 2024 12:46 ET
|
Research and Markets
Dublin, April 16, 2024 (GLOBE NEWSWIRE) -- The "Vulvar Cancer - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.The report provides comprehensive...